Regeneron Acquires 23andMe for $256 Million Amid Privacy Concerns and Data Breach Fallout
Regeneron Pharmaceuticals confirms its acquisition of 23andMe, the once-prominent consumer genetic testing firm, for $256 million through a bankruptcy auction. The transaction…